HKHeejeong Kim

Heejeong Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heejeong Kim has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Developmentally Guided Differentiation of Ventral Midbrain Dopaminergic Cells Validated in Proteopathy‐Based Parkinson's Disease Models

    by Heechang Moon, Heejeong Kim, Elliot H. Lee, Hanseul Kim, Ji Hun Kim, Huisu Jeong, Jiwon Cheon, Ga Ram Jeong, Byoung Dae Lee, Jae‐Won Cho, et al.

    Parkinson's disease (PD) involves progressive degeneration of nigrostriatal ventral midbrain dopaminergic (vmDA) neurons and Lewy body proteopathy, necessitating scalable, lineage‐faithful donor cells. However, variability in human pluripotent stem cell (hPSC) differentiation and incomplete ventral midbrain identity limit translational use. Here, we establish a developmentally guided differentiation protocol that reproducibly specifies EN1‐positive vmDA progenitors through temporally optimized SHH, WNT/β‐catenin, and FGF8 signaling. The resulting progenitors mature into vmDA neurons exhibiting stimulus‐dependent dopamine release and maturation‐associated pacemaking activity. Progenitors can be cryopreserved at a defined stage while retaining viability and neurogenic capacity. Functional validation was performed using complementary proteopathy‐based PD models. In vitro, optogenetic induction of α‐synuclein aggregation ( OASIS ) triggered robust aggregate formation and selective degeneration of TH‐positive vmDA neurons in both two‐dimensional cultures and three‐dimensional neurospheroids. In vivo, we established a conditional β23 proteopathy‐based PD mouse model exhibiting progressive nigrostriatal degeneration and motor impairment. Transplantation of hESC‐derived vmDA progenitors into advanced‐stage PD mice led to graft survival, differentiation into vmDA neurons, and significant motor improvement. Together, these findings define a robust vmDA differentiation framework validated across proteopathy‐based disease modeling and transplantation contexts, supporting its application in PD modeling and cell therapy.

  • Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion

    by Sangwoo Ham, Seung Pil Yun, Hyojung Kim, Donghoon Kim, Bo Am Seo, Heejeong Kim, Jeong-Yong Shin, Mohamad Aasif Dar, Gum Hwa Lee, Yun Il Lee, et al.

    Pathological AIMP2 aggregation leads to α-synuclein inclusion and dopaminergic toxicity in Parkinson’s disease.